1-3 of 3
Björn H. Rüter
Close
Sort by
Journal Articles

Low-Dose Decitabine (DAC), Alone or in Combination with All-Trans Retinoic Acid (ATRA), Is An Active First-Line Treatment in Older AML Patients of All Cytogenetic Risk Groups: Final Results of the FR00331 Multicenter Phase II Study.

Michael Lübbert, Björn H. Rüter, Mathias Schmid, Rainer Claus, Ulrich Germing, Volker Rethwisch, Arnold Ganser, Uwe Platzbecker, Oliver Galm, Wolfram Brugger, Gerhard Heil, Björn Hackanson, Barbara Deschler, Pierre W Wijermans, Claudia Schmoor, Hartmut Döhner
Journal: Blood
Blood (2009) 114 (22): 4141.
https://doi.org/10.1182/blood.V114.22.4141.4141
Published: 2009
Journal Articles

Non-Intensive AML/MDS Treatment with Low-Dose Decitabine Prior to Reduced-Intensity Conditioning (RIC) and Allogeneic Blood Stem Cell Transplantation of Older Patients.

Michael Lübbert, MD, PhD, Hartmut Bertz, MD, PhD, Björn H. Rüter, MD, Roland H. Mertelsmann, MD, PhD, Jürgen Finke, MD, PhD
Journal: Blood
Blood (2006) 108 (11): 5257.
https://doi.org/10.1182/blood.V108.11.5257.5257
Published: 2006
Journal Articles

Re-Treatment with Low-Dose 5-Aza-2′-Deoxycytidine (Decitabine) Results in Second Remissions of Previously Responsive MDS Patients.

Michael Lübbert, MD, PhD, Pierre W. Wijermans, MD, PhD, Björn H. Rüter, MD
Journal: Blood
Blood (2004) 104 (11): 1447.
https://doi.org/10.1182/blood.V104.11.1447.1447
Published: 2004